Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21765276 | 0.84 | GABRA1 (0.35) | GABRA1GABRB1GABRB2 | |
| SCHEMBL11985992 | 0.77 | ALDH1A1 (0.47) | GABRA1GABRB1TTRLMNA | |
| SCHEMBL28713389 | 0.74 | TTR (0.48) | GABRA1GABRB1GABRB2TTR | |
| SCHEMBL12295394 | 0.74 | LMNA (0.38) | GABRA1GABRB1LMNA | |
| SCHEMBL12889907 | 0.74 | EIF4A3 (0.40) | GABRA1GABRB1GABRB2LMNA | |
| SCHEMBL15082621 | 0.72 | GABRA1 (0.61) | GABRA1GABRB1GABRB2TTRLMNA | |
| SCHEMBL8817829 | 0.72 | LMNA (0.32) | GABRA1GABRB1LMNA | |
| SCHEMBL12160545 | 0.72 | HSD17B10 (0.52) | GABRA1GABRB1TTRLMNA | |
| SCHEMBL807533 | 0.72 | CYP3A4 (0.52) | GABRA1GABRB1LMNA | |
| SCHEMBL16180760 | 0.72 | TTR (0.35) | TTRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309240-B2 | Pyrazolopyridine compounds, compositions and methods of use | GENENTECH, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-09-26 | — | — | US | disclosed |
| US-8486950-B2 | Janus kinase inhibitor compounds and methods | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-08-09 | — | — | US | disclosed |
| WO-2012066061-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDINES AND THEIR USE AS TYK2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2010142752-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252941-A1 | PYRAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | P2RX5, P2RX4, P2RY1 | GABRA1 1498/4885GABRB1 2024/4885GABRB2 2350/4885 |
| US-20100317643-A1 | JANUS KINASE INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | GABRA1 984/4885GABRB1 872/4885GABRB2 1131/4885 |
| US-20140171408-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | GABRA1 1006/4885GABRB1 960/4885GABRB2 925/4885 |
| US-20120202788-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F12, CHRM1, NPY1R | GABRA1 1006/4885GABRB1 960/4885GABRB2 925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.